Sugi Predict

Sugi Predict / Compounds / SCHEMBL922535

SCHEMBL922535

SCHEMBL922535

Nc1nn(-c2ccccc2)c(N)c1/N=N/c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 14/20 1.00
▸ RAB9A P51151 11/20 1.00
▸ NPC1 O15118 10/20 1.00
▸ SMN1; SMN2 Q16637 9/20 1.00
▸ LMNA P02545 5/20 1.00
▸ NFKB1 P19838 4/20 1.00
▸ NFKB2 Q00653 4/20 1.00
▸ RELA Q04206 4/20 1.00
▸ PLA2G1B P04054 2/20 1.00
▸ ATG4B Q9Y4P1 2/20 1.00
▸ TDP1 Q9NUW8 8/20 0.81
▸ MAPK1 P28482 7/20 0.74
▸ HPGD P15428 3/20 0.72
▸ ALDH1A1 P00352 1/20 0.72
▸ GAA P10253 2/20 0.67
▸ ATM Q13315 1/20 0.64
▸ ALOX5 P09917 4/20 0.61
▸ PTGS2 P35354 4/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.59
▸ MEN1 O00255 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922536 1.00 MAPT (1.00) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL924385 0.90 MAPT (0.81) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL924386 0.90 MAPT (0.81) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL32675998 0.90 MAPT (1.00) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL922340 0.90 MAPT (0.81) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL922341 0.90 MAPT (0.81) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL922400 0.86 MAPT (0.74) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL922399 0.86 MAPT (0.74) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL13592685 0.85 MAPT (0.74) MAPTRAB9ANPC1SMN1; SMN2LMNA
SCHEMBL8999235 0.84 SMN1; SMN2 (1.00) MAPTRAB9ANPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 — — US claimed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 — — US claimed
US-6436915-B1 ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS KINETEK PHARMACEUTICALS, INC. (CA) 2002-08-20 — — US claimed
US-20020042501-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2002-04-11 — — US claimed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 — — US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 — — US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 — — US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 — — US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 — — US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 — — US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 — — EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 — — WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 — — US disclosed
EP-1276723-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY Kinetek Pharmaceuticals, Inc. (CA) 2003-01-22 — — EP disclosed
US-6436915-B1 ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS KINETEK PHARMACEUTICALS, INC. (CA) 2002-08-20 — — US disclosed
US-20020042501-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2002-04-11 — — US disclosed
WO-2001077080-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY KINETEK PHARMACEUTICALS, INC. (CA) 2001-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885RAB9A 4545/4885NPC1 2611/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885RAB9A 4545/4885NPC1 2611/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MAPT 4000/4885RAB9A 3555/4885NPC1 3205/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C MAPT 4486/4885RAB9A 4226/4885NPC1 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.